CJC-1295 with DAC

Why scientists study it

• It is a long-acting copy of GHRH(1-29) whose added linker, the Drug Affinity Complex (DAC), bonds to albumin in the blood and is credited in animal and lab studies with keeping it in plasma far longer than the natural fragment used in No DAC products.
• In animals and in early human studies, one injection kept growth hormone (GH) and IGF-1 raised until the next, and the pituitary was reported to keep releasing GH in pulses instead of a steady stream.
• Scientists study it next to the No DAC form and GHRP compounds like ipamorelin, which work through the ghrelin (GHS) receptor instead, to explore ways of stimulating GH through both routes at once.

Three studies to know

Teichman et al., 2006 · The Journal of Clinical Endocrinology & Metabolism

Healthy adults in this early-phase study got CJC-1295 under the skin, once or repeatedly. Teichman and colleagues saw GH and IGF-1 release stay raised for a long time, more so at higher doses. Read the paper

Jetté et al., 2005 · Endocrinology

Jetté and colleagues set out the DAC chemistry that joins a peptide to albumin. Working with tissue from the front of the rat pituitary, they described CJC-1295 as a long-lasting agonist of the GRF receptor, meaning it switches that receptor on. Read the paper

Alba et al., 2006 · American Journal of Physiology-Endocrinology and Metabolism

Mice with the GHRH gene knocked out make no GHRH of their own. They got CJC-1295 once a day, and their body weight and length were normal. Alba and colleagues showed that the analog can stand in for the missing GHRH in living animals. Read the paper

Safety and legal status

• It is an experimental research compound. As of 2026 it has no approval from the FDA, the EMA or the MHRA for treating people.
• It is a GHRH analog, a class the World Anti-Doping Agency lists under S2 with growth hormone secretagogues and related substances.
• For laboratory research use only. It is not for human use.